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Abstract
Background: Elevated serum uric acid (SUA) is associated with poor prognosis in patients with cardiovascular disease,
yet it is still not decided whether the role of SUA is causal or only reflects an underlying disease. The purpose of the
study was to investigate if SUA was an independent predictor of 5-year all-cause mortality in a propensity score
matched cohort of chronic heart failure (HF) outpatients. Furthermore, to assess whether gender or renal function
modified the effect of SUA.
Methods: Patients (n = 4684) from the Norwegian Heart Failure Registry with baseline SUA were included in the
study. Individuals in the highest gender-specific SUA quartile were propensity score matched 1:1 with patients in
the lowest three SUA quartiles. The propensity score matching procedure created 928 pairs of patients (73.4% males,
mean age 71.4 ± 11.5 years) with comparable baseline characteristics. Kaplan Meier and Cox regression analyses were
used to investigate the independent effect of SUA on all-cause mortality.
Results: SUA in the highest quartile was an independent predictor of all-cause mortality in HF outpatients (hazard ratio
(HR) 1.19, 95% confidence interval (CI) 1.03–1.37, p-value 0.021). Gender was found to interact the relationship between
SUA and all-cause mortality (p-value for interaction 0.007). High SUA was an independent predictor of all-cause mortality
in women (HR 1.65, 95% CI 1.24–2.20, p-value 0.001), but not in men (HR 1.06, 95% CI 0.89–1.25, p-value 0.527). Renal
function did not influence the relationship between SUA and all-cause mortality (p-value for interaction 0.539).
Conclusions: High SUA was independently associated with inferior 5-year survival in Norwegian HF outpatients.
The finding was modified by gender and high SUA was only an independent predictor of 5-year all-cause mortality in
women, not in men.
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Background
The relationship between elevated serum uric acid (SUA)
and cardiovascular (CV) disease and mortality is well
recognized [1, 2], yet it is still undecided whether the asso-
ciation reflects a causal inference or whether SUA is a risk
marker reflecting the burden of the underlying disease.
SUA, the end product of purine metabolism in humans,
is catalysed by xanthine oxidase (XO) and predominantly
eliminated by the kidneys [3]. Renal function, gender, race,
and medication may all influence SUA level [2]. In addition,
genetic studies have uncovered variants in urate reabsorp-
tion and excretion transporters that are responsible for
some variation in SUA level [4].
High SUA in heart failure (HF) may result from impaired
oxidative metabolism causing accumulation of uric acid
precursors and increased XO activation [5] as well as from
decreased renal elimination as chronic kidney disease
(CKD) is highly prevalent [6].
High SUA levels have been found to be related to inci-
dent HF [7–10] and to be associated with poor outcomes
in HF patients [11–14]. An association between SUA and
incident, prevalent and progressive CKD has also been
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detected [15–17] but the results concerning effect of SUA
on mortality in CKD patients are inconsistent [18–21].
Cardiovascular risk factors and outcomes differ between
men and women [22]. Gender differences are also apparent
in HF patients, both with regard to aetiology, left ventricle
ejection fraction (LVEF) and prognosis [23–26]. The associ-
ation between SUA and CV disease outcomes appears to
be more pronounced in women than in men [7, 27, 28] but
the role of gender in the relationship between SUA and sur-
vival of HF patients is not yet clearly determined.
Reducing the effect of confounding is crucial when es-
timating associations in observational studies. Propensity
score matching is a statistical method that accounts for
confounding variables in a different manner than trad-
itional multivariate Cox proportional hazards model and
might be a superior method [29].
The aim of the current study was to examine whether
SUA is an independent predictor of all-cause mortality
in a propensity score matched cohort of Norwegian HF
outpatients. Furthermore, we aimed to analyse if the
effect of SUA on all-cause mortality is modified by gender
or renal function.
Methods
The Norwegian heart failure registry
The Norwegian Heart Failure Registry has collected data
on outpatients referred to HF clinics in Norwegian
hospitals since 2000. By February 2012, a total of 6675 pa-
tients were enrolled by 25 HF clinics in different Norwegian
regions that cover about half of Norway’s population. The
participating HF clinics were run by cardiologists and
specialized nurses. Patients were registered after they
had been diagnosed with chronic HF of any aetiology
following the guidelines of the European Society of Cardi-
ology (ESC) [30, 31]. Three visits were recorded. At the
time of the first visit (baseline), medical history, physical
examination, echocardiography, New York Heart Associ-
ation (NYHA) functional class, laboratory results, and the
medical management of HF were recorded. The last ad-
justment visit was recorded at stable follow-up, after the
multidisciplinary team had optimized the treatment and
the patient had participated in an educational program. At
the time of the third visit, arranged 6 months after the last
adjustment visit, patient’s health condition was reassessed,
as well as medication and laboratory results. Mortality
data are retrieved yearly from Statistics Norway.
Study population
A total of 4953 (74.2%) patients in the Norwegian Heart
Failure Registry had available baseline measurements of
SUA and were eligible for the study. The patients in each
reporting hospital were grouped into gender specific SUA
quartiles, as the participating hospitals used different la-
boratory assays for SUA analyses and the recommended
reference range of SUA differs for women and men
(women 18–49 years: 155–350 μmol/l, women over 50
years: 155–400 μmol/l, men: 230–480 μmol/l) [32]. Subjects
from hospitals with less than 40 registered subjects were
excluded to achieve proper stratification. Consequently,
4684 patients from 19 hospitals were stratified and included
in the analyses. Finally, patients in each SUA quartile were
merged together across hospitals and gender, comprising
about 1180 subjects in each group.
Definitions
Renal function was expressed as estimated glomerular
filtration rate (eGFR) and calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation [33]. Reduced renal function was defined as
eGFR< 60 ml/min/1.73 m2.
Based on 2016 ESC Guidelines on HF [34], LVEF was
defined as reduced at < 40% and as preserved at ≥50%.
Diagnosis of hypertension was based on information
on antihypertensive treatment.
Daily doses of angiotensin-converting enzyme inhibitors
(ACEi) were converted to enalapril equivalent doses (enal-
april 20mg = lisinopril 20mg = ramipril 10mg = captopril
100mg), and then expressed as percent of enalapril target
dose. Target dose of enalapril was defined as 20mg per
day. Daily doses of loop diuretics were converted to fur-
osemide equivalent doses (furosemide 40mg = bumeta-
nide 1mg). Daily doses of β-blockers were converted to
metoprolol equivalent doses (metoprolol 200mg = biso-
prolol 10mg = carvedilol 50mg = atenolol 100mg).
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation and categorical variables as frequencies (per-
centage). Differences in continuous variables were com-
pared by one-way analysis of variance and Student t-test
as required. Similarly, differences in categorical variables
were compared by χ2 test. The two-tailed significance level
test was set to p < 0.05.
An individual propensity score, the likelihood of SUA
being in the highest quartile, was obtained for each patient
using a multivariate logistic regression model. Baseline vari-
ables found to be associated with SUA in the highest quar-
tile (p-value < 0.10) and variables that could potentially
confound the relationship between SUA and mortality were
chosen as independent variables when calculating the pro-
pensity score. The following 16 covariates were entered in
the model: gender, age, body mass index (BMI), smoking,
diabetes mellitus, claudication and/or previous stroke,
systolic blood pressure, NYHA functional class, use of
renin-angiotensin-system (RAS)-blocking agents, β-blocker
dose, diuretic dose, use of statin, eGFR, haemoglobin,
serum sodium and serum potassium. Patients with SUA
in the fourth quartile were then matched 1:1 to patients
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Table 1 Baseline characteristics of HF outpatients before and after propensity score matching, by SUA quartiles
Quartiles of SUA in 4684 HF outpatients 1856 HF Outpatients after PSM







Se-uric acid, μmol/L 310.6 ± 51.5 405.4 ± 35.8 490.3 ± 36.5 635.2 ± 88.2 < 0.001 427.7 ± 80.3 633.3 ± 85.3 < 0.001
Se-uric acid, mg/dL 5.22 ± 0.87 6.82 ± 0.60 8.24 ± 0.61 10.68 ± 1.48 7.19 ± 1.35 10.65 ± 1.43
Male gender, % 73.0 73.7 74.5 71.9 0.527 73.5 73.3 0.916
Age, years 68.0 ± 12.8 68.8 ± 11.9 69.5 ± 12.1 71.9 ± 11.1 < 0.001 71.3 ± 11.3 71.4 ± 11.7 0.770
Body mass index, kg/m2 25.3 ± 4.7 26.2 ± 5.0 27.0 ± 5.3 26.9 ± 5.3 < 0.001 26.5 ± 5.2 26.6 ± 5.1 0.683
Smoking, % 18.5 15.9 13.8 13.0 0.001 14.3 13.8 0.738
Medical history
Diabetes mellitus, % 15.9 18.7 19.8 24.0 < 0.001 20.8 21.6 0.691
Ischaemic heart disease, % 55.1 54.5 56.1 58.1 0.334 57.8 57.5 0.919
Hypertension, % 22.9 32.8 33.7 38.8 < 0.001 36.8 38.7 0.395
Claudication/stroke, % 13.6 14.8 15.2 17.2 0.106 17.6 17.1 0.806
PCI/CABG, % 37.2 39.8 37.7 37.7 0.575 38.7 38.6 0.968
Reduced renal function, % 21.6 31.9 47.4 71.9 < 0.001 67.1 68.5 0.518
Physical findings
Heart rate, beats/min 71.8 ± 14.3 71.9 ± 14.4 73.0 ± 15.5 73.6 ± 15.5 0.008 74.5 ± 16.1 73.7 ± 15.3 0.265
SBP, mmHg 127.9 ± 22.2 128.1 ± 22.7 127.0 ± 21.7 123.4 ± 22.5 < 0.001 125.3 ± 22.0 124.4 ± 22.4 0.398
LVEF, % 33.4 ± 11.1 32.7 ± 11.2 32.4 ± 11.6 32.4 ± 12.5 0.131 32.3 ± 11.7 32.2 ± 12.7 0.956
LVEF groups 0.171 0.557
LVEF< 40% 72.2 74.6 73.2 74.9 74.3 75.6
40%≤ LVEF< 50% 18.6 16.3 18.1 14.6 16.0 14.1
LVEF≥50% 9.2 9.1 8.7 10.6 9.8 10.3
NYHA Class < 0.001 0.548
I + II, % 58.4 52.2 47.8 37.6 39.8 36.9
III + IV, % 41.7 47.9 52.3 62.4 60.3 63.0
Medication
RAS-blocking agent use, % 89.0 90.8 90.1 87.2 0.027 88.8 88.1 0.663
ACEi dose/day, % of target dose 48.1 ± 36.4 53.1 ± 37.8 54.9 ± 38.0 52.9 ± 41.8 0.001 51.6 ± 38.3 53.1 ± 42.2 0.486
ARB use, % 14.2 14.7 16.8 17.4 0.089 16.6 17.0 0.804
β-blocker dose/day, mg 61.1 ± 58.2 74.2 ± 67.4 72.3 ± 61.8 77.7 ± 66.7 < 0.001 76.8 ± 66.1 75.2 ± 65.6 0.605
Loop diuretics dose/day, mg 34.4 ± 43.9 47.6 ± 53.6 62.9 ± 48.5 87.5 ± 72.5 < 0.001 72.2 ± 70.5 83.4 ± 70.4 0.001
Calcium channel blocker use, % 7.4 8.2 8.3 8.4 0.785 8.9 7.3 0.225
Acetylsalicylic acid use, % 51.3 47.9 45.5 43.4 0.001 44.5 43.4 0.644
Statin use, % 56.0 56.1 54.3 51.8 0.124 51.9 51.6 0.889
Laboratory values
eGFR, ml/min/1.73m2 75.3 ± 20.4 69.2 ± 20.5 62.6 ± 21.0 50.9 ± 20.7 < 0.001 54.1 ± 19.8 52.9 ± 20.8 0.205
Haemoglobin, g/100 mL 13.79 ± 1.57 14.00 ± 1.65 13.89 ± 1.72 13.70 ± 1.89 < 0.001 13.78 ± 1.78 13.75 ± 1.85 0.700
Se-potassium, mmol/L 4.38 ± 0.41 4.41 ± 0.43 4.38 ± 0.49 4.41 ± 0.52 0.136 4.43 ± 0.50 4.40 ± 0.50 0.280
Se-sodium, mmol/L 139.7 ± 3.3 140.0 ± 3.1 140.0 ± 3.2 139.7 ± 3.4 0.024 139.8 ± 3.3 139.7 ± 3.3 0.530
Se-cholesterol, mmol/L 4.65 ± 1.23 4.71 ± 1.22 4.79 ± 1.31 4.72 ± 1.33 0.097 4.73 ± 1.29 4.75 ± 1.31 0.745
Values are expressed as mean ± SD or percent. ACEi dose/day, percent of daily enalapril equivalent target dose; ARB, angiotensin receptor blocker; β-blocker dose/
day, daily metoprolol equivalent dose; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association; PCI/CABG, percutaneous coronary intervention and/or coronary artery bypass graft; PSM, propensity score matching; RAS-blocking agent, renin-
angiotensin system blocking agent; SBP, systolic blood pressure; SUA, serum uric acid
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with SUA in quartiles 1–3 on the propensity score,
using match tolerance of 0.05 with no replacement and
preference to exact match.
Five-year survival curves were presented using Kaplan-
Meier statistics. Univariate Cox proportional hazards model
was used in the propensity score matched cohort and pre-
sented as hazard ratio (HR) and 95% confidential interval
(95% CI). Due to the limited number of female patients,
multivariable Cox proportional hazards model was used
when evaluating the effect of SUA on all-cause mortality in
the gender-stratified model. Baseline variables found to be
associated with SUA in the highest quartile in women
(p-value< 0.10) were included in the multivariate model:
age, BMI, smoking, ischaemic heart disease, diabetes melli-
tus, hypertension, NYHA functional class, systolic blood
pressure, LVEF, use of RAS-blocking agents, β-blocker
dose, diuretic dose, eGFR, and serum sodium.
All statistical analyses were performed using IBM SPSS
Statistics version 25 (IBM SPSS Statistics, New York,
USA). Kaplan Meier survival curves were obtained using
STATA/SE version 14.1 (StataCorp LP, Texas, USA).
Results
Baseline characteristics and propensity score matching
Baseline characteristics of the 4684 included HF outpa-
tients are presented by SUA quartiles in Table 1. The
mean age was 69.6 ± 12.2 years and 73.3% were males.
Patients in higher SUA quartiles were more prone to be
older, to have a history of diabetes and hypertension,
more severe HF symptoms, higher BMI and worse renal
function compared to patients in the lower SUA quar-
tiles. They used higher doses of diuretics and β-blockers
and were less likely to use RAS-blocking agents and
acetylsalicylic acid. The median follow-up was 50 (inter-
quartile range (IQR) 27, 78) months.
Kaplan-Meier survival curves for SUA in quartiles 1–3
were almost superimposable and all-cause mortality for
individuals with SUA in quartile 4 was significantly greater
than for those with SUA in quartiles 1–3 (log-rank < 0.001,
Fig. 1). Individuals with SUA in the lowest three quartiles
were therefore all selected to be potential controls in the
propensity matched model. A total of 928 subjects with
SUA in quartile 4 were matched 1:1 by propensity score
to subjects with SUA in quartiles 1–3. Baseline charac-
teristics of the 1856 propensity score matched subjects
were well-balanced (Table 1).
Survival analyses and outcomes based on SUA level
SUA in the highest quartile was an independent pre-
dictor of all-cause mortality in HF outpatients (HR 1.19,
95% CI 1.03–1.37, p-value 0.021, Fig. 2).
Gender was found to interact the relationship between
SUA and all-cause mortality in the propensity matched
model (p-value for interaction 0.007). Differences in the
survival of HF outpatients depending on gender and
SUA quartile are depicted in Kaplan-Meier survival
curves in Fig. 3. High SUA was an independent predictor
of all-cause mortality in women (HR 1.65, 95% CI 1.24–
2.20, p-value 0.001) but not in men (HR 1.06, 95% CI
0.89–1.25, p-value 0.527). Renal function did not interact
the relationship between SUA and all-cause mortality
(p-value for interaction 0.539).
Women and men with SUA in the highest quartile dif-
fered both in age, comorbidity, medication, and physical
and laboratory findings from those with lower SUA
(Table 2). The number of female patients was limited and
a gender-stratified propensity matched model was not
possible. Subsequently, gender specific multivariate Cox
proportional hazard model analyses in the subgroups of
1251 female and 3433 male HF outpatients were performed
Fig. 1 Kaplan-Meier survival plot of 4684 HF outpatients according to SUA quartile
Stubnova et al. BMC Cardiovascular Disorders            (2019) 19:4 Page 4 of 10
to further explore gender differences in the prognostic
value of SUA on survival. In the subgroup of female HF
outpatients, SUA in the highest quartile was confirmed to
be an independent predictor of all-cause mortality (HR
1.51, 95% CI 1.13–2.02, p-value 0.005). On the contrary,
SUA did not independently predict all-cause mortality in
the subgroup of male HF outpatients (HR 1.10, 95% CI
0.94–1.30, p-value 0.249).
Discussion
The current study demonstrates that high level of SUA
was an independent predictor of 5-year all-cause mortality
in patients with chronic HF. The finding was gender spe-
cific and only found in women. To our knowledge, this is
the first propensity score matched study to report the gen-
der modifying effect on the relationship between SUA and
all-cause mortality in chronic HF. The predictive value of
SUA on mortality was not modified by renal function.
Other studies have found an association between high
levels of SUA and poor outcome in chronic HF patients
[13, 21, 35–37], still the causal relationship is considered
undecided. We report SUA in the fourth quartile to be
an independent predictor of all-cause mortality select-
ively in women, both in the propensity score matched
model and multivariate Cox regression model.
Gender differences in the effect of SUA on outcomes
have been reported previously in patients with CV disease.
In hypertensive patients with left ventricular hypertrophy,
the association between SUA and CV events was reported
to be stronger in women than in men [28]. A study of pa-
tients with acute coronary syndrome showed that SUA was
predictive of CV events in women but not in men [38].
Similarly, in a population based survey, SUA was found to
be an independent predictor of mortality in women only
[27]. Our results now expand the evidence for gender differ-
ences in the effect of SUA also to be valid in HF outpatients.
Fig. 3 Kaplan-Meier survival plot of propensity score matched HF outpatients according to gender and SUA quartile
Fig. 2 Kaplan-Meier survival plot of 1856 HF outpatients propensity score matched by SUA in quartile 4
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In most previous studies assessing differences in survival
between men and women with HF, women have been re-
ported to have better survival than men [25, 39–44]. Sex
hormones affect myocardial calcium handling, nitric oxide,
glucose and fatty metabolism as well as cardiac fibrosis, and
may participate in the mechanisms for differences between
female and male failing hearts [26]. SUA is a potent antioxi-
dant but at the same time, SUA and XO lead to reduced
nitric oxide bioavailability, ensuing endothelial dysfunction,
inflammation and vasoconstriction [45]. Menopause has
been found to be associated with increasing SUA, possibly
due to altered effect of oestrogen on renal tubular handling
of uric acid [46]. We did not have information on meno-
pausal status in female HF outpatients in the current study,
but the mean age of 72.1 ± 12.1 years implies that the great
majority were postmenopausal. Our study revealed distinct
differences between women and men with SUA in quartile
4 with regard to age, type, symptoms and treatment of HF,
as well as comorbidity and renal function. Still, both the
propensity score matched model and multivariate Cox
regression model identified SUA in the highest quartile
to be a predictor of all-cause mortality in women inde-
pendently of the above mentioned confounding vari-
ables. The mechanisms for the deteriorating effect of
high SUA on survival selectively in postmenopausal
women need to be further explored, yet our findings
may imply SUA being a future treatment target in female
HF patients. Urate-lowering therapy is currently not rec-
ommended in asymptomatic hyperuricemia due to limited
benefit-risk data in non-gout diseases [47]. Nevertheless,
XO-inhibiting therapy has been shown to have beneficial
effects in some patient groups [48]. In HF patients with
hyperuricemia, XO-inhibition did not improve survival,
but it is noteworthy that the study was not gender strati-
fied and only of 24-week duration [49].
Renal function did not modify the effect of SUA on
all-cause mortality in the present study. This corrobo-
rates the observation by Anker et al. [13] who also found
SUA to be a predictor of poor outcome in HF independ-
ent of renal function, while Filippatos et al. [21] found
SUA to be associated with poor outcome only in HF pa-
tients without CKD. Studies exploring SUA impact in
patients with CKD show inconsistent results [18–20].
Some limitations of our study need to be considered.
Because of various laboratory assays for SUA analyses in
the reporting hospitals, we grouped patients in each
hospital into gender-specific SUA quartiles. Small groups
may cause a systematic error and therefore we did not
include patients from hospitals with less than 40 registered
individuals. On the other hand, we might have introduced a
selection bias by excluding some hospitals. Patients in each
SUA quartile were merged together across hospitals and
gender, eventually leading to some overlapping SUA values
in the four quartiles.
We used both propensity score method and multivariate
Cox regression method to reduce the bias by confounding.
Propensity score matching is an increasingly used method
that mimics some characteristics of randomized control
trials (RCT) and makes it possible to directly compare
outcomes in the two studied groups [29]. We used pro-
pensity score matching when assessing the impact of high
SUA on survival in all HF outpatients. Propensity score
for having SUA in the highest quartile was estimated
based on 16 measured baseline variables. Two groups of
patients were established based on propensity score, dif-
fering in the presence or absence of SUA in the fourth
quartile and, similarly to RCTs, we could then directly
compare survival in the groups. Distribution of baseline
characteristic in the propensity matched groups was
well-balanced except for daily doses of diuretics. However,
the difference was minor and is unlikely to explain the dis-
parity in survival. Furthermore, the large size of the study
population and the high number of variables used for esti-
mation of propensity score and the fact that nearly 80% of
patients with SUA in the highest quartile were propensity
score matched should ensure reliability of our results. In
the gender stratified analyses, we used multivariate Cox
proportional hazard model to correct for the confounding
variables as propensity score matching would lead to small
size of the examined groups and thus could possibly intro-
duce a selection bias. Yet, neither propensity score match-
ing nor multivariate Cox proportional hazards method
can correct for unmeasured confounding variables.
The current study is observational and therefore re-
stricted to the existing data in the Norwegian Heart Failure
Registry. We could not influence selection of the collected
variables. Information on alcohol consumption, losartan
use, hormone replacement therapy, the use of SUA lower-
ing drugs, thyroid function, and triglycerides level could
have added valuable information. At the same time, the
observational nature of this study is among its strengths as
the included patients represent a relatively unselected
population in contrast to highly selected subjects in RCTs.
Conclusions
SUA in the highest quartile was independently associated
with inferior 5-year survival in Norwegian HF outpatients.
The finding was modified by gender and high SUA was
only an independent predictor of 5-year all-cause mortal-
ity in women but not in men. Our findings indicate that
SUA might be a therapeutic target selectively in female
HF patients. Renal function did not modify the effect of
SUA on all-cause mortality.
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